Business
Trading update - Media comment and speculation
Aptamer Group plc has issued a trading update to address media comment and speculation, confirming that its current cash position provides a runway through to June 2027, consistent with previous statements. This update reassures investors regarding the company's financial stability and operational outlook. Disclaimer*
About this update from Aptamer Group Plc
[{"type":"text","content":"\n\n \n7 January 2026\n \nAptamer Group plc\n \n(\"Aptamer\", the \"Company\" or the \"Group\")\n \nTrading update - Media comment and speculation\n \nAptamer Group plc (AIM: APTA), the developer of next-generation synthetic binders for the life sciences industry, provides an update regarding media comment and speculation following the trading update released by the Company earlier today. The Company confirms that the Group's cash position provides a runway through to June 2027 in line with the previous statements (see RNS 14 October 2025, \"Full year results for the twelve months ended 30 June 2025\").\n \n- Ends -\n \n For further information, please contact: \n \n\n\n\n\nAptamer Group plc \nDr Arron Tolley, Chief Executive Officer\n\n\n+44 (0) 1904 217 404 \n\n\n\n\nSPARK Advisory Partners Limited - Nominated Adviser \nAndrew Emmott \n\n\n+44 (0) 20 3368 3550 \n\n\n\n\nTurner Pope Investments (TPI) Limited - Broker \nAndrew Thacker / Guy McDougall \n\n\n+44 (0) 20 3657 0050 \n\n\n\n\nNorthstar Communications Limited - Investor Relations\nSarah Hollins \n\n\n+44 (0) 113 730 3896\n\n\n\n\n \nAbout Aptamer Group\n \nAptamer Group is a leading developer of next-generation synthetic binders delivering innovation to the life sciences industry. The Group develops Optimer® binders, advanced molecules that work like antibodies by attaching to specific targets in the body. These binders are used in medicine, diagnostic tests, and research tools, offering benefits like high stability, reliable performance, and lower costs compared to traditional antibodies.\n \nAptamer operates a fee-for-service business in the US$210 billion market for antibody alternatives, working with all top 10 global pharmaceutical companies. It is also building valuable Optimer® assets with partners, aiming for future licensing revenue.\n \nFounded in 2008, the Group listed on the London Stock Exchange AIM market in December 2021 and is headquartered in York, UK.\n \nTo register for news alerts by email go to https://aptamergroup.com/investors/investor-news-email-alerts/\n \n \n \n \n\n","length":5480,"tagName":"div"}]